Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning?

Niraj Shenoy, Mythri Mudireddy, Rangit Vallapureddy, Nelson Leung, Lance Pagliaro, Thomas Witzig, Fang Shu Ou, Tamas Ordog, John Cheville, Mrinal Patnaik, R. Houston Thompson, Ayalew Tefferi, Kebede Begna

Research output: Contribution to journalArticle

Abstract

After clinical observations of patients with a personal history of both renal cell carcinoma (RCC) and myelodysplastic syndromes (MDSs), we sought to explore a potential association between the 2, using Mayo Clinic's ‘Advanced Cohort Explorer’ database. The prevalence of MDS in patients > 65 years with a personal history of nephrectomy for RCC was ≈8.4 times that of the age-concordant general population based on the Dusseldorf registry (28/6490 or 395/100,000 vs. ≈47/100,000; P < .001), and 3.07 times that of the age-concordant patient population at Mayo Clinic (28/6490 or 395/100,000 vs. 128.4/100,000; P < .001). Given the degree of association, this information is important for the development of survivorship care plans for patients with RCC. To our knowledge, this is the first study describing the link between RCC and MDSs. Background: Renal cell carcinoma (RCC) and certain myeloid malignancies are both characterized by widespread aberrant DNA hypermethylation. After clinical observations of patients with a personal history of both malignancies, we sought to explore a potential association, and to describe the clinical characteristics of these patients. Patients and Methods: Mayo Clinic's ‘Advanced Cohort Explorer’ database was used to identify patients with a history of both malignancies. Clinical features and long-term outcome were abstracted. Prevalence of myelodysplastic syndromes (MDSs) in patients ≥ 65 years with a personal history of nephrectomy for RCC was then compared with the prevalence of MDSs in the Dusseldorf MDS registry and the general patient population at Mayo Clinic, using 1-sample test of proportions. Results: A total of 59 patients with a diagnosis of both RCC and myeloid malignancy were identified. The myeloid malignancies included 38 MDSs, 12 acute myelogenous leukemia, and 9 myeloproliferative neoplasms. The cohort was characterized by marked male predominance (4.4:1). The median age at RCC diagnosis was 64 years (range, 37-87 years), and for myeloid malignancy was 75 years (range, 44-90 years). Prevalence of MDS in patients > 65 years with a personal history of nephrectomy for RCC was ≈ 8.4 times that of the age-concordant general population based on the Dusseldorf registry (28/6490 or 395/100,000 vs. ≈ 47/100,000; P < .001), and 3.07 times that of the age-concordant patient population at Mayo Clinic (28/6490 or 395/100,000 vs. 128.4/100,000; P < .001). Conclusions: We observed a strong association between RCC and MDS. Patients with a history of RCC appear to have a substantially increased risk of developing MDS compared with the general population.

Original languageEnglish (US)
Pages (from-to)e1117-e1122
JournalClinical Genitourinary Cancer
Volume16
Issue number6
DOIs
StatePublished - Dec 2018
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Renal Cell Carcinoma
Epigenomics
Nephrectomy
Population
Registries
Databases

Keywords

  • Kidney cancer
  • MDS
  • Myelodysplasia
  • RCC
  • Risk

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes : Epigenetic Underpinning? / Shenoy, Niraj; Mudireddy, Mythri; Vallapureddy, Rangit; Leung, Nelson; Pagliaro, Lance; Witzig, Thomas; Ou, Fang Shu; Ordog, Tamas; Cheville, John; Patnaik, Mrinal; Thompson, R. Houston; Tefferi, Ayalew; Begna, Kebede.

In: Clinical Genitourinary Cancer, Vol. 16, No. 6, 12.2018, p. e1117-e1122.

Research output: Contribution to journalArticle

Shenoy, N, Mudireddy, M, Vallapureddy, R, Leung, N, Pagliaro, L, Witzig, T, Ou, FS, Ordog, T, Cheville, J, Patnaik, M, Thompson, RH, Tefferi, A & Begna, K 2018, 'Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning?', Clinical Genitourinary Cancer, vol. 16, no. 6, pp. e1117-e1122. https://doi.org/10.1016/j.clgc.2018.06.008
Shenoy, Niraj ; Mudireddy, Mythri ; Vallapureddy, Rangit ; Leung, Nelson ; Pagliaro, Lance ; Witzig, Thomas ; Ou, Fang Shu ; Ordog, Tamas ; Cheville, John ; Patnaik, Mrinal ; Thompson, R. Houston ; Tefferi, Ayalew ; Begna, Kebede. / Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes : Epigenetic Underpinning?. In: Clinical Genitourinary Cancer. 2018 ; Vol. 16, No. 6. pp. e1117-e1122.
@article{4a38646de8ac4e67bf02b183770e035f,
title = "Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning?",
abstract = "After clinical observations of patients with a personal history of both renal cell carcinoma (RCC) and myelodysplastic syndromes (MDSs), we sought to explore a potential association between the 2, using Mayo Clinic's ‘Advanced Cohort Explorer’ database. The prevalence of MDS in patients > 65 years with a personal history of nephrectomy for RCC was ≈8.4 times that of the age-concordant general population based on the Dusseldorf registry (28/6490 or 395/100,000 vs. ≈47/100,000; P < .001), and 3.07 times that of the age-concordant patient population at Mayo Clinic (28/6490 or 395/100,000 vs. 128.4/100,000; P < .001). Given the degree of association, this information is important for the development of survivorship care plans for patients with RCC. To our knowledge, this is the first study describing the link between RCC and MDSs. Background: Renal cell carcinoma (RCC) and certain myeloid malignancies are both characterized by widespread aberrant DNA hypermethylation. After clinical observations of patients with a personal history of both malignancies, we sought to explore a potential association, and to describe the clinical characteristics of these patients. Patients and Methods: Mayo Clinic's ‘Advanced Cohort Explorer’ database was used to identify patients with a history of both malignancies. Clinical features and long-term outcome were abstracted. Prevalence of myelodysplastic syndromes (MDSs) in patients ≥ 65 years with a personal history of nephrectomy for RCC was then compared with the prevalence of MDSs in the Dusseldorf MDS registry and the general patient population at Mayo Clinic, using 1-sample test of proportions. Results: A total of 59 patients with a diagnosis of both RCC and myeloid malignancy were identified. The myeloid malignancies included 38 MDSs, 12 acute myelogenous leukemia, and 9 myeloproliferative neoplasms. The cohort was characterized by marked male predominance (4.4:1). The median age at RCC diagnosis was 64 years (range, 37-87 years), and for myeloid malignancy was 75 years (range, 44-90 years). Prevalence of MDS in patients > 65 years with a personal history of nephrectomy for RCC was ≈ 8.4 times that of the age-concordant general population based on the Dusseldorf registry (28/6490 or 395/100,000 vs. ≈ 47/100,000; P < .001), and 3.07 times that of the age-concordant patient population at Mayo Clinic (28/6490 or 395/100,000 vs. 128.4/100,000; P < .001). Conclusions: We observed a strong association between RCC and MDS. Patients with a history of RCC appear to have a substantially increased risk of developing MDS compared with the general population.",
keywords = "Kidney cancer, MDS, Myelodysplasia, RCC, Risk",
author = "Niraj Shenoy and Mythri Mudireddy and Rangit Vallapureddy and Nelson Leung and Lance Pagliaro and Thomas Witzig and Ou, {Fang Shu} and Tamas Ordog and John Cheville and Mrinal Patnaik and Thompson, {R. Houston} and Ayalew Tefferi and Kebede Begna",
year = "2018",
month = "12",
doi = "10.1016/j.clgc.2018.06.008",
language = "English (US)",
volume = "16",
pages = "e1117--e1122",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes

T2 - Epigenetic Underpinning?

AU - Shenoy, Niraj

AU - Mudireddy, Mythri

AU - Vallapureddy, Rangit

AU - Leung, Nelson

AU - Pagliaro, Lance

AU - Witzig, Thomas

AU - Ou, Fang Shu

AU - Ordog, Tamas

AU - Cheville, John

AU - Patnaik, Mrinal

AU - Thompson, R. Houston

AU - Tefferi, Ayalew

AU - Begna, Kebede

PY - 2018/12

Y1 - 2018/12

N2 - After clinical observations of patients with a personal history of both renal cell carcinoma (RCC) and myelodysplastic syndromes (MDSs), we sought to explore a potential association between the 2, using Mayo Clinic's ‘Advanced Cohort Explorer’ database. The prevalence of MDS in patients > 65 years with a personal history of nephrectomy for RCC was ≈8.4 times that of the age-concordant general population based on the Dusseldorf registry (28/6490 or 395/100,000 vs. ≈47/100,000; P < .001), and 3.07 times that of the age-concordant patient population at Mayo Clinic (28/6490 or 395/100,000 vs. 128.4/100,000; P < .001). Given the degree of association, this information is important for the development of survivorship care plans for patients with RCC. To our knowledge, this is the first study describing the link between RCC and MDSs. Background: Renal cell carcinoma (RCC) and certain myeloid malignancies are both characterized by widespread aberrant DNA hypermethylation. After clinical observations of patients with a personal history of both malignancies, we sought to explore a potential association, and to describe the clinical characteristics of these patients. Patients and Methods: Mayo Clinic's ‘Advanced Cohort Explorer’ database was used to identify patients with a history of both malignancies. Clinical features and long-term outcome were abstracted. Prevalence of myelodysplastic syndromes (MDSs) in patients ≥ 65 years with a personal history of nephrectomy for RCC was then compared with the prevalence of MDSs in the Dusseldorf MDS registry and the general patient population at Mayo Clinic, using 1-sample test of proportions. Results: A total of 59 patients with a diagnosis of both RCC and myeloid malignancy were identified. The myeloid malignancies included 38 MDSs, 12 acute myelogenous leukemia, and 9 myeloproliferative neoplasms. The cohort was characterized by marked male predominance (4.4:1). The median age at RCC diagnosis was 64 years (range, 37-87 years), and for myeloid malignancy was 75 years (range, 44-90 years). Prevalence of MDS in patients > 65 years with a personal history of nephrectomy for RCC was ≈ 8.4 times that of the age-concordant general population based on the Dusseldorf registry (28/6490 or 395/100,000 vs. ≈ 47/100,000; P < .001), and 3.07 times that of the age-concordant patient population at Mayo Clinic (28/6490 or 395/100,000 vs. 128.4/100,000; P < .001). Conclusions: We observed a strong association between RCC and MDS. Patients with a history of RCC appear to have a substantially increased risk of developing MDS compared with the general population.

AB - After clinical observations of patients with a personal history of both renal cell carcinoma (RCC) and myelodysplastic syndromes (MDSs), we sought to explore a potential association between the 2, using Mayo Clinic's ‘Advanced Cohort Explorer’ database. The prevalence of MDS in patients > 65 years with a personal history of nephrectomy for RCC was ≈8.4 times that of the age-concordant general population based on the Dusseldorf registry (28/6490 or 395/100,000 vs. ≈47/100,000; P < .001), and 3.07 times that of the age-concordant patient population at Mayo Clinic (28/6490 or 395/100,000 vs. 128.4/100,000; P < .001). Given the degree of association, this information is important for the development of survivorship care plans for patients with RCC. To our knowledge, this is the first study describing the link between RCC and MDSs. Background: Renal cell carcinoma (RCC) and certain myeloid malignancies are both characterized by widespread aberrant DNA hypermethylation. After clinical observations of patients with a personal history of both malignancies, we sought to explore a potential association, and to describe the clinical characteristics of these patients. Patients and Methods: Mayo Clinic's ‘Advanced Cohort Explorer’ database was used to identify patients with a history of both malignancies. Clinical features and long-term outcome were abstracted. Prevalence of myelodysplastic syndromes (MDSs) in patients ≥ 65 years with a personal history of nephrectomy for RCC was then compared with the prevalence of MDSs in the Dusseldorf MDS registry and the general patient population at Mayo Clinic, using 1-sample test of proportions. Results: A total of 59 patients with a diagnosis of both RCC and myeloid malignancy were identified. The myeloid malignancies included 38 MDSs, 12 acute myelogenous leukemia, and 9 myeloproliferative neoplasms. The cohort was characterized by marked male predominance (4.4:1). The median age at RCC diagnosis was 64 years (range, 37-87 years), and for myeloid malignancy was 75 years (range, 44-90 years). Prevalence of MDS in patients > 65 years with a personal history of nephrectomy for RCC was ≈ 8.4 times that of the age-concordant general population based on the Dusseldorf registry (28/6490 or 395/100,000 vs. ≈ 47/100,000; P < .001), and 3.07 times that of the age-concordant patient population at Mayo Clinic (28/6490 or 395/100,000 vs. 128.4/100,000; P < .001). Conclusions: We observed a strong association between RCC and MDS. Patients with a history of RCC appear to have a substantially increased risk of developing MDS compared with the general population.

KW - Kidney cancer

KW - MDS

KW - Myelodysplasia

KW - RCC

KW - Risk

UR - http://www.scopus.com/inward/record.url?scp=85050810337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050810337&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2018.06.008

DO - 10.1016/j.clgc.2018.06.008

M3 - Article

C2 - 30077464

AN - SCOPUS:85050810337

VL - 16

SP - e1117-e1122

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 6

ER -